Market Announcement



8 August 2023

Limeade Inc. (ASX: LME) – Suspension from Quotation

Description

The securities of Limeade Inc. ('LME') will be suspended from quotation immediately under Listing Rule 17.2, at the request of LME, following the special meeting of shareholders approving the merger between LME and WebMD Health Corp.

Issued by

Renee Hutchens Adviser, Listings Compliance



Email

8 August 2023

Ms Renee Hutchens Listings Compliance ASX Compliance Pty Ltd Exchange Centre Level 6, 20 Bridge Street Sydney, NSW 2000

Dear Renee

Limeade, Inc. (ASX:LME) - Request for Suspension of Limeade CDIs

Limeade, Inc. (Limeade) requests an immediate suspension to the trading of its CDIs on the ASX.

The suspension has been requested as Limeade has received shareholder approval for the merger between Limeade and WebMD Health Corp (**Merger**).

In accordance with ASX Listing Rule 17.2, Limeade provides the following information:

- Limeade requests the suspension of Limeade's CDIs, having received shareholder approval for the Merger, to facilitate the closing of the Merger;
- Limeade requests the suspension of its CDIs from official quotation until Limeade requests to be removed from the official list of the ASX;
- The request for removal from the official list is expected to be made following the effective time specified in the Articles of Merger to be filed with the Secretary of State of the State of Washington in accordance with the provisions of the Washington Business Corporation Act, Title 23B of the Revised Code of Washington; and
- Limeade is not aware of any reason why its securities should not be suspended, or of any other information necessary to inform the market about the suspension.

Yours sincerely

— DocuSigned by: Sarah Vishuk — 4F28901C3FEE489...

Sarah Visbeek

General Counsel and Corporate Secretary

Limeade, Inc

8/8/2023